Novel Ru(III), Rh(III), Pd(II) and Pt(II) complexes with ligands incorporating azole and pyrimidine rings. I. Antiproliferative activity in vitro

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 1, 2000, Pages 51-55

  Wiśniewski, Marek Z ^a   Wietrzyk, Joanna ^b   Opolski, Adam ^b  

^a JAN KOCHANOWSKI UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Azole and pyrimidine complexes; Cytotoxic activity in vitro; Human cancer cell lines; Platinum group metal complexes

Indexed keywords

PALLADIUM COMPLEX; PLATINUM COMPLEX; RHENIUM COMPLEX; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; COLON CANCER; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL DIVISION; FEMALE; HUMANS; LIGANDS; METALS, HEAVY; ORGANOMETALLIC COMPOUNDS; ORGANOPLATINUM COMPOUNDS; PALLADIUM; RHODIUM; RUTHENIUM; TUMOR CELLS, CULTURED;

EID: 0342749349     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BULT A. (1983): Methods involving metal ions and complexes in clinical chemistry. In SIEGEL H. (ed.): Metal complexes of sulfanilamides in pharmaceutical analysis and therapy. Marcel Dekker, Inc., New York-Basel, 261-276.
2. CIEPLIK J. (1992): Synthesis of news pyrimidine derivatives with cytostatic activity. Wiad. Chem., 46, 377-401.
3. COLETTA F., ETTORE R. and GAMBARO A. (1975): Palladium(II) and platinum(II) complexes of 3,5-dimethylpyrazole. J. Inorg. Nucl. Chem., 37, 314-316.
4. GERAN R. I., GREENBERG N. H., MACDONALD M. M., SCHUMACHER A. M. and ABBOTT B. J. (1972): Protocols for screening of chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3, 59-61.
5. JONES M. M. (1976): Therapeutic chelating agents. J. Chem. Educ., 53, 342-347.
6. JONES M. M. (1985): An alternative model for the selection of therapeutic chelating agents. Inorg. Chim. Acta, 107, 235-241.
7. KAIM W. and SCHWEDERSKI B. (1994): Chemotherapy with compounds of some nonessential elements. In MEYER G. and NAKAMURA A. (eds.): Inorganic elements in the chemistry of life. John Wiley and Sons, Chichester-New York-Brisbane-Toronto-Singapure, 363-378.
8. 5). Inorg. Chim., 26, 844-846.
9. KOZŁOWSKI H. (1988): Leki nieorganiczne w chorobach i niedoborach. Zeszyty Naukowe WSP, Opole, 9, 19-43.
10. KUDUK-JAWORSKA J. (1992): Przeciwnowotworowo aktywne kompleksy platyny. Wydawnictwo Uniwersytetu Wrocławskiego, Wroclław, 29-34.
11. LIVINGSTONE S. E. (1973): Palladium; platinum. In TROTMAN-DICENSON A. F. (ed.): The chemistry of ruthenium, rhodium, palladium, osmium, iridium and platinum. Pergamon Press, Oxford-New York-Toronto-Sydney-Paris, 188-189; 274-275.
12. MASKOS K. (1988): Oddziaływanie jonów metali z kwasami nukleinowymi. Krystalograficzne badania kompleksów metali z nukleotydami. Wiad. Chem., 35, 735-767.
13. MATTERN I. E., COCCHIARELLA L., VAN KRALINGEN C. G. and LOHMAN P. H. (1982): Prophage induction and mutagenicity of a series of anti-tumour platinum(II) and platinum(IV) co-ordination complexes. Mutat. Res., 95, 79-93.
14. 2, a platinum(II) complex with a styrylbenzothiazole ligand. Acta Crystallogr. C, 44, 803-806.
15. ROSENBERG B., VAN CAMP L., TROSKO J. E. and MANSOUR V. H. (1969): Platinum compounds: a new class of potent antitumour agents. Nature, 222, 385-386.
16. SKEHAN P., STORENG R., SCUDIERO D., MONKS A., MCMAHON J., VISTICA D., WARREN J. T., BOKESCH H., KENNEY S. and BOYOL M. R. (1990): New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst., 82, 1107-1112.
17. SURGA W. J., WIŚNIEWSKI M. Z. and REPKA A. (1995): Coordination compounds of ruthenium(III), rhodium(III), palladium(II) and platinum(II) with 2-mercaptopyrimidine. Pol. J. Chem., 69, 540-545.
18. TAQUIKHAN B., ANNAPOORNA K., SHAMSUDDIN S. and NAJMUDDIN K. (1992): Mixed ligand complexes of cis-dichloromethionineplatinum(II) and cis-dichloromethioninepalladium(II) with substitutes pyrimidines. Polyhedron, 11, 2109-2114.
19. VAN DER VEER J. L. and REEDIJK J. (1988): Investigation antitumour drug mechanism. Chem. Brit., 24, 775-789.
20. VAN KRALINGEN C. G. and REEDIJK J. (1978): Coordination compounds of Pt(II) with N-methylimidazole as ligand. Inorg. Chim. Acta, 30, 171-177.
21. WILLIAMS D. R. (1972): Metals, ligands and cancer. Chem. Rev., 72, 202-213.
22. WIŚNIEWSKI M. Z. and GŁLOWIAK T. (1998): The structure and properties of a palladium(II) complex of 2-mercapto-1-methylimidazole. Pol. J. Chem., 72, 514-518.
23. WIŚNIEWSKI M. Z., GŁOWIAK T. and SURGA W. J. (1998): Co-ordination compounds of Pd(II) and Pt(II) with 3,4,5,6-tetrahydro-2-pyrimidinethiol. Pol. J. Chem., 72, 2226-2231.
24. WIŚNIEWSKI M. Z., SURGA W. J. and LENARCIK B. (1990): Co-ordination compounds of 2-mercapto-1-methylimidazole with platinum(II), palladium(II), rhodium(III) and ruthenium(III). Trans. Met. Chem., 15, 63-65.
25. WIŚNIEWSKI M. Z., SURGA W. J. and OPOZDA E. M. (1994): Palladium methylpyrazole complexes. Trans. Met. Chem., 19, 353-354.